Piribedil

證據等級: L5

預測適應症: 5 個

Piribedil: From Parkinson’s Disease to Retinal Dystrophy with or Without Extraocular Anomalies

One-Sentence Summary

Piribedil is a dopamine D2/D3 receptor agonist approved for Parkinson’s disease in France and several Asian markets, with one active registration in Malaysia. The TxGNN model predicts it may be effective for Retinal Dystrophy with or Without Extraocular Anomalies, supported by 0 clinical trials and 15 retrieved publications — none of which appear to directly investigate this drug-disease combination. The mechanistic link is very weak, and the high prediction score likely reflects a knowledge graph artefact rather than genuine biological plausibility.

Quick Overview

Item	Content
Original Indication	Not available in Malaysia regulatory data (internationally known indication: Parkinson’s disease)
Predicted New Indication	Retinal Dystrophy with or Without Extraocular Anomalies
TxGNN Prediction Score	99.34%
Evidence Level	L5
Malaysia Market Status	✓ Marketed
Number of Registrations	1
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Based on known information, Piribedil is a dopamine D2/D3 receptor agonist (with additional alpha-2 adrenoceptor antagonist properties), whose efficacy in Parkinson’s disease has been clinically established through direct stimulation of dopaminergic pathways in the nigrostriatal system. It is approved in France and several Asian countries as a first- or adjunct-line agent for Parkinson’s motor symptoms.

The mechanistic link to retinal dystrophy with or without extraocular anomalies is theoretically very weak. Hereditary retinal dystrophies are caused by mutations affecting ciliary function, photoreceptor structure, or retinal pigment epithelium biology — pathways entirely unrelated to dopaminergic signalling. While the retina does contain dopaminergic amacrine cells that modulate light adaptation, their involvement does not translate into a plausible therapeutic pathway for progressive photoreceptor degeneration.

The high TxGNN score (99.34%) is most likely an artefact of knowledge graph over-generalization: the “dopaminergic → neurodegeneration” connectivity in the graph is broad enough to span structurally unrelated diseases such as hereditary retinopathy. This interpretation is supported by the fact that the 15 retrieved publications describe orbital anatomy, extraocular muscle disorders, and congenital ocular anomalies — none of which directly investigate Piribedil in the context of retinal dystrophy. By contrast, the Rank 2 and Rank 4–5 predictions (juvenile-onset Parkinson syndromes and PLA2G6-associated neurodegeneration with parkinsonism) carry substantially stronger mechanistic rationale and warrant prioritization over this indication.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

⚠️ Relevance Notice: The following 15 publications were retrieved by keyword matching on “retinal dystrophy with or without extraocular anomalies.” After review, none of the papers directly investigate Piribedil in this condition. All relevance assessments remain pending. The publications primarily address orbital pathology, congenital extraocular muscle disorders, and developmental ocular anomalies that are unrelated to this drug-disease pairing.

PMID	Year	Type	Journal	Key Findings
38321238	2024	Review	Pediatric Radiology	Differential diagnosis of pediatric orbital lesions, covering congenital and developmental ocular pathologies including microphthalmos, coloboma, and Coats disease
38249493	2023	Review	Taiwan Journal of Ophthalmology	Congenital lens shape anomalies; discusses structural and developmental defects with potential association to anterior segment dysgenesis
37408430	2023	Review	Chinese Journal of Ophthalmology	Structure and innervation of extraocular muscles; pulley tissue abnormalities and their role in strabismus
33806565	2021	Research Article	International Journal of Molecular Sciences	Optic nerve and retinal abnormalities in congenital fibrosis of extraocular muscles (CFEOM); explores whether KIF21A/TUBB3 mutations extend beyond the oculomotor system
30196776	2018	Review	Journal of Binocular Vision and Ocular Motility	Classification of congenital cranial dysinnervation disorders (CCDDs); ophthalmoplegia subtypes and diagnostic confirmation strategies
27930425	2017	Anatomical Study	Ophthalmic Plastic and Reconstructive Surgery	Description of the anomalous gracillimus orbitis accessory extraocular muscle found in cadaver dissections
22241537	2012	Review	Klinische Monatsblätter für Augenheilkunde	Congenital ptosis: levator muscle fatty dystrophy, fibrosis, and association with refractive errors and binocular vision disturbance
20127583	2010	Clinical Guide	Seminars in Neurology	Systematic history-taking and examination approach to diplopia; differential diagnosis of ocular, neurologic, and extraocular muscle disorders
9416661	1997	Review/Case Series	Seminars in Ultrasound, CT, and MR	Orbital infections: five-stage classification of periorbital cellulitis secondary to sinusitis; systemic predisposing conditions
7035111	1981	Case Series	Documenta Ophthalmologica	Wagner-Stickler syndrome complex: vitreoretinal degeneration, myopia, and extraocular manifestations including sensorineural deafness and skeletal dysplasia

Malaysia Market Information

The regulatory data confirms 1 active registration for Piribedil in Malaysia (NPRA status: Marketed). However, specific authorization details — including authorization number, product name, dosage form, and approved indication text — are not available in the current evidence pack.

Authorization Number	Product Name	Dosage Form	Approved Indication
—	—	—	Details not available in current evidence pack; please verify via NPRA official portal

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: Despite a TxGNN score of 99.34%, there is no clinical trial evidence and no directly relevant literature supporting Piribedil use in hereditary retinal dystrophies. The dopamine D2/D3 agonist mechanism of Piribedil does not address the ciliary dysfunction or photoreceptor degeneration underlying this condition, and the high score most likely reflects over-generalization within the knowledge graph’s neurodegeneration node cluster.

To proceed, the following is needed:

Retrieve the Malaysia NPRA package insert to confirm the approved indication text and complete safety profile (key warnings, contraindications)
Obtain full MOA data from DrugBank (DB12478) to enable proper mechanistic analysis
Conduct a targeted literature search specifically combining “piribedil” AND (“retinal dystrophy” OR “photoreceptor” OR “retinitis pigmentosa”) to exclude any overlooked direct evidence
Re-examine the TxGNN graph topology to determine whether the prediction arises from an overgeneralized “dopaminergic → neurodegeneration” pathway, and consider down-weighting this edge type for ophthalmological indications
Prioritize the higher-plausibility predictions instead: Rank 2 (Hunt’s juvenile paralysis agitans), Rank 4 (PLA2G6-associated neurodegeneration/PARK14), and Rank 5 (juvenile onset Parkinson disease 19A) all involve dopaminergic pathway dysfunction and carry meaningfully stronger mechanistic rationale for Piribedil repurposing — these should be advanced to the next evaluation stage ahead of the retinal dystrophy indication
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.